ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment optionsJean‐Jacques Kiladjian, Christoph Klade, Francisca Ferrer‐Marín et al.|Annals of Hematology|2024Cited by 14